Ocugen has announced the publication of positive results from its phase 1 GARDian1 trial of OCU410ST, a gene therapy for ...

Ocugen, Inc. gene therapy outlook: key 2026 catalysts, Phase 2/3 eye-disease data, BLA plans to 2028, and risks. Click for ...

Study supports favorable safety and tolerability profile and clinically meaningful functional and structural benefits in ...

Canva research shows Gen Z in India favour visual-first work, with poor visual communication linked to delays and inefficiencies A new study from Canva highlights a widening disconnect between how Gen ...